📚 Compounding Pharmacies 101

Editors’ Note: We’re excited to share our website with you! It features a healthspan-focused job board, an archive of past newsletters, a growing dictionary of terms we’ve highlighted in previous editions and more to come!

Visit us at: https://stacked-health.com/

Or copy and paste this link to others: {{rp_refer_url}}

Top engineers at Anthropic and OpenAI say AI now writes 100% of their code.

If you're not using AI, you're spending 40 hours doing what they do in 4.

These 100+ Claude Code hacks fix that and help you ship 10x faster.

Sign up for The Code and get:

Claim your free playbook

Last Thursday and Friday, 14 people sat in a conference room on the FDA's campus in Silver Spring and voted on whether the peptide BPC-157 should be legal to make in the United States (read our Peptide 101). The Pharmacy Compounding Advisory Committee recommended 6 of 7 peptides for approval. The committee broke with the FDA's own staff, who had recommended against all six in advance.

Almost nobody outside the industry noticed, but that room is where a large part of the American drug supply gets decided. Understanding why requires understanding compounding pharmacies. They are the least-explained important institution in healthcare.

What a compounding pharmacy actually does

A normal pharmacy dispenses finished products made by a manufacturer. A compounding pharmacy makes the drug itself, mixing raw active pharmaceutical ingredients with other components to produce something that does not exist as an approved commercial product.

The original justification is unglamorous and completely legitimate. A child cannot swallow a tablet, so a pharmacist turns it into a liquid. A patient reacts badly to a dye in the commercial formulation, so a pharmacist makes a version without it. A manufacturer discontinued something that a few thousand people still need.

Here is the part that matters. Compounded drugs are not FDA-approved. There is no premarket review of safety or effectiveness. The FDA does not evaluate the product at all. Compounding exists as a carve-out from the approval system, on the logic that individualized medicine cannot realistically be run through a process designed for mass-produced pharmaceuticals.

For most of the 20th century that carve-out was small enough that nobody thought hard about it. Then it killed people.

Why there are two kinds

The modern framework was built in 2013 in response to the New England Compounding Center disaster, in which contaminated injections produced a fungal meningitis outbreak that killed dozens of patients. The facility was operating at industrial scale under rules written for a corner pharmacist making a custom cream. Congress responded by splitting compounding into two lanes.

A 503A pharmacy is state-licensed and compounds against individual patient-specific prescriptions, under the oversight of state boards of pharmacy. This is the traditional model. Oversight is local and uneven.

A 503B outsourcing facility registers with the FDA, follows manufacturing standards close to those imposed on real drug manufacturers, and is permitted to produce sterile medications in batches without a prescription for a named patient. This is the industrial lane, created so that the next New England Compounding Center would be inspected like the factory it actually was. 

Only the 503B lane can supply a national direct-to-consumer business, because only the 503B lane can make a product before it knows who will take it. 

The rule that opens the valve

Compounders are not permitted to make copies of commercially available approved drugs. If that rule were absolute, compounding would remain a small business.

When a drug appears on the FDA's official shortage list, the copying prohibition lifts, and both 503A pharmacies and 503B facilities may produce their own versions. The logic is: if patients cannot get an approved drug, a compounded one is better than nothing. That conditional clause is the pressure-release valve. 

What got built in the gap

Semaglutide products went onto the shortage list in 2022, and tirzepatide followed the same year. Novo Nordisk and Eli Lilly could not manufacture fast enough to meet demand, so the copying prohibition was lifted on the two most sought-after drugs in America.

An industry appeared almost immediately. Telehealth platforms paired a remote prescriber with a 503B facility and sold compounded semaglutide direct to consumers at a fraction of brand pricing. Brand list prices at the time ran above $1,000 per month, with injectable Wegovy listed at $1,349, while compounded versions were commonly sold in the low hundreds. Compounded products reached close to 30% of US GLP-1 supply at the 2024 peak. 

A supply failure at two manufacturers created a temporary legal opening, and hundreds of companies built permanent-looking businesses inside it. Marketing budgets and Super Bowl ads rested on a shortage designation that could be revoked by an administrative decision.

The quality question was never resolved either. By early 2025 the FDA had logged more than 455 adverse event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide, with many stemming from patients drawing incorrect doses out of multidose vials, some requiring hospitalization. 

The unwind

Tirzepatide came off the shortage list in 2024 and semaglutide came off in February 2025. The FDA set wind-down deadlines of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. On paper, the industry was over. 

Companies pivoted to a personalization argument, claiming that individually tailored doses of compounded GLP-1s were not copies of the approved products and therefore remained legal. The dispute moved from whether compounding was permitted to how much variation makes something a different drug.

Manufacturers have removed the price argument for compounding. Injectable Wegovy and Ozempic are now offered around $199 per month through direct cash-pay channels, the Wegovy pill at $149, and Zepbound starting at $299. When the approved product costs what the compounded copy costs, the valve has no pressure left to release.

The valve is now opening somewhere else

Which brings us back to Silver Spring. Research peptides like BPC-157 have sat outside that list for years, which is why they circulate through gray-market vendors labeled as research chemicals rather than through licensed pharmacies.

The July votes do not change that yet. They are recommendations, they carry no immediate legal effect, and the FDA must still run formal notice-and-comment rulemaking before any of these substances can be legally compounded. That process typically takes six to twelve months, and the agency is not bound by the committee's advice.

But the direction is the point. The same administrative machinery being used to shut down compounded GLP-1s is being pointed the other way for peptides, in the same month, by the same agency.

Why you should care

Most people think a drug is either legal or illegal. Compounding shows that drug status is conditional, and that the conditions can change without legislation, litigation, or any public event you would notice.

If you take a compounded medication, your access depends on administrative (not clinical) status. In the current peptide market, nothing you can currently buy from a gray-market vendor became legal last week, and the gap between a committee vote and an actual rule is where the misleading marketing will live for the next year. 

A molecule's legal status can flip because a committee voted, or because an agency published a notice nobody read, and neither event looks like news at the time. If you want to know what will be available to you a year from now, the FDA's bulks lists will tell you before any pharmacy does. The valve is closing on GLP-1s. Watch which molecule it opens on next.

Or copy and paste this link to others: {{rp_refer_url}}

Current Referral Count: {{rp_num_referrals}}